Merck (MRK) Cash & Current Investments (2009 - 2026)

Merck (MRK) has reported Cash & Current Investments for 18 consecutive years, with $5.7 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments fell 38.21% year-over-year to $5.7 billion; the TTM figure through Mar 2026 stood at $5.7 billion (down 38.21% YoY), while the FY2025 annual figure was $14.6 billion, up 6.4% from the prior year.
• Cash & Current Investments declined to $5.7 billion in Q1 2026 per MRK's latest filing, from $14.6 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $18.2 billion in Q3 2025 and bottomed at $5.6 billion in Q1 2024.
• Historically, Cash & Current Investments has averaged $10.5 billion across 5 years, with a median of $10.1 billion in 2022.
• Annual changes were most pronounced in 2023 — Cash & Current Investments sank 46.23% — and 2024, when it jumped 92.99%.
• Merck's Cash & Current Investments stood at $13.2 billion in 2022, then tumbled by 46.23% to $7.1 billion in 2023, then jumped by 92.99% to $13.7 billion in 2024, then grew by 6.4% to $14.6 billion in 2025, then tumbled by 60.85% to $5.7 billion in 2026.
• Business Quant data shows MRK's Cash & Current Investments at $5.7 billion in Q1 2026, $14.6 billion in Q4 2025, and $18.2 billion in Q3 2025.